RBC Capital analyst Conor McNamara lowered the firm’s price target on Hologic (HOLX) to $85 from $88 and keeps a Sector Perform rating on the shares after its Q1 results. Despite lowering organic revenue growth by about 250bps for FY25, the management maintained its EPS view thanks to accelerated buybacks and expense discipline, but with new revenue headwinds pressuring growth in 2025, RBC remains at a neutral rating, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls
- Hologic price target lowered to $90 from $95 at Raymond James
- Hologic downgraded to Market Perform from Outperform at Leerink
- Hologic Reports Modest Revenue Growth in Q1 2025
- Hologic backs FY25 adjusted EPS view $4.25-$5.35, consensus $4.25